TG4-155 is a brain penetrant prostaglandin EP2 specific antagonist.
TG4-155 is a brain penetrant prostaglandin EP2 specific antagonist. TG4-155 has a 4730X selectivity over EP4 (2.4 nM vs 11.4 mM in binding assays), and a 7 fold selectivity over DP1 receptors. TG4-155 crosses the blood brain barrier, and has no antagonistic effects on EP4 signaling, and displays neuroprotective effects in a pilocarpine-induced status epilepticus (SE) seizure model. TG4-155 does not interfere with G-protein function or phosphodiesterase activity, and does not inhibit COX-1 or COX-2.
British journal of pharmacology, 176(11), 1680-1699 (2019-02-15)
An up-regulation of COX-2 in malignant gliomas causes excessive synthesis of PGE2 , which is thought to facilitate brain tumour growth and invasion. However, which downstream PGE2 receptor subtype (i.e., EP1 -EP4 ) directly contributes to COX activity-promoted glioma growth
Questions
Évaluations
★★★★★ Aucune valeur de notation
Filtres actifs
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..